CREON® (PANCRELIPASE) DELAYED-RELEASE CAPSULES SIGNIFICANTLY IMPROVES FAT ABSORPTION IN CHILDREN WITH CYSTIC FIBROSIS, STUDY IN CLINICAL THERAPEUTICS REPORTS February 05, 2010
Solvay Pharmaceuticals, Inc. announced today that Phase IIIb data published in the January issue of Clinical Therapeutics confirm that CREON® (pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in children aged 7-11 years who have exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), EPI is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food.
High-Achieving Students with Cystic Fibrosis Receive More Than
$200,000 Total in Higher Education Scholarships from SolvayCARES September 15, 2009
Solvay Pharmaceuticals, Inc. today announced that it has donated scholarships totaling more than $200,000 to nearly 250 students living with cystic fibrosis (CF) through its SolvayCARES Scholarship program. Each year, 40 students receive a one-year scholarship of $2,500 to help finance post-secondary education; however, as a special recognition this year, every eligible 2009 applicant was honored with a $500 scholarship.
Solvay Pharmaceuticals Announces the Influenza Research Grant Topic for 2010 September 14, 2009
Solvay Pharmaceuticals announces the topic of the 2010 Solvay Pharmaceuticals Influenza Research Grant (SPIRG). Applications are now being invited for the 2010 Research Grant for new or existing research projects aimed at innovative research into methods of improving influenza vaccine uptake among healthcare workers.
SOLVAY PHARMACEUTICALS, INC. ANNOUNCES COMMERCIAL AVAILABILITY OF CREON® (PANCRELIPASE) DELAYED-RELEASE CAPSULES July 07, 2009
Solvay Pharmaceuticals, Inc. today announced the commercial availability of CREON® (pancrelipase) Delayed-Release Capsules. Now available to be filled at pharmacies nationwide, CREON® was approved by the Food and Drug Administration (FDA) on April 30, 2009, for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) or other conditions.
New Initiative Urges Women to Address Men’s Health this New Year January 05, 2009
Nine out of 10 women in the United States are unaware that if their husband or male partner experiences symptoms like fatigue, depressed mood and increased waistline it could be related to a condition known as low testosterone, or Low T, according to survey results announced today by Solvay Pharmaceuticals, Inc.
Solvay Pharmaceuticals, Inc. Names Elizabeth M. Mutisya, M.D., Vice President of Medical Affairs and Chief Medical Officer December 15, 2008
Solvay Pharmaceuticals, Inc. announced today that Elizabeth M. Mutisya, M.D., was named vice president of U.S. Medical Affairs and Chief Medical Officer. In this role, Mutisya will lead the Medical Affairs function, responsible for medical education, medical marketing strategies, medical communications, medical information, drug safety, investigator-sponsored studies, educational grants and professional advisory boards.
New Subset Analysis of AndroGel® Data Highlights Efficacy -- Regardless of BMI June 17, 2008
Solvay Pharmaceuticals, Inc. announced today that a new analysis of pivotal study data conducted by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center showed that initial treatment response of hypogonadal men with AndroGel® (testosterone gel) 1% CIII had similar effects on subjects, regardless of weight and body mass index (BMI). These study results were presented today at the 2008 Endocrine Society Annual Meeting (ENDO) in San Francisco.
Dr. Stephen Hill Named to PhRMA Board of Directors May 06, 2008
Solvay Pharmaceuticals, Inc. announced today that Stephen Hill, B.M., B.Ch., M.A., F.R.C.S., president and chief executive officer, has been named to the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Shannon Thyme Klinger Named Senior Vice President and General Counsel for Solvay Pharmaceuticals, Inc. March 13, 2008
Solvay Pharmaceuticals, Inc. announced today that on January 2, 2008, Shannon Thyme Klinger was named senior vice president and general counsel. In this role, Ms. Klinger directs all legal matters for the company as well as oversees the activities of the government affairs and corporate communications functions for the company in the U.S. She serves as a member of the U.S. Pharmaceutical Leadership Team.
Solvay Pharmaceuticals to Co-Promote Abbott's SIMCOR in the United States October 22, 2007
Solvay Pharmaceuticals has entered into an agreement granting Solvay select co-promotion rights in the United States for Abbott's investigational fixed-dose combination lipid therapy, SIMCOR® (Niaspan®/simvastatin), currently awaiting U.S. Food and Drug Administration (FDA) approval.
Solvay Pharmaceuticals Awards 100 College Scholarships to Students with Cystic Fibrosis October 16, 2007
Solvay Pharmaceuticals, Inc. announced today that it awarded scholarships to 100 students with cystic fibrosis (CF). The 100 SolvayCARES Scholarships were awarded to every eligible applicant this year in celebration of the 15th anniversary of the scholarship program, which supports students pursuing any form of education beyond the high school level.
Solvay Pharmaceuticals, Inc. Announces FDA Extension of Tedisamil PDUFA Date September 26, 2007
Solvay Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued an extension to the Prescription Drug User Fee Act (PDUFA) deadline in order to complete its review of the New Drug Application (NDA) submitted for tedisamil, an investigational compound for the treatment of recent onset atrial fibrillation or atrial flutter.
Solvay Pharmaceuticals, Inc. Receives Approvable Letter from FDA With Respect to New Drug Application for CREON® August 20, 2007
Solvay Pharmaceuticals, Inc. today announced it has received an approvable letter from the U.S. Food and Drug Administration (FDA) with respect to its New Drug Application (NDA) for CREON®. CREON® (pancrelipase delayed-release capsules, USP) is a pancreatic enzyme for the treatment of pancreatic exocrine insufficiency as is often associated with cystic fibrosis and chronic pancreatitis.
New Long-Term Data Analyses for Bifeprunox Show Favorable Effects vs. Placebo in Stabilized Patients with Schizophrenia May 22, 2007
Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), and Lundbeck A/S presented clinical study results on bifeprunox, an investigational treatment for adult patients diagnosed with schizophrenia, today at the 2007 annual meeting of the American Psychiatric Association. New analyses of six-month data in stabilized adult patients with schizophrenia from a double-blind, placebo-controlled study demonstrated that bifeprunox maintained stability vs. placebo and displayed a favorable weight and lipid profile comparable with placebo.
Victor F. C. Raczkowski, M.D., M.S., Named Vice President of U.S. Regulatory Affairs for Solvay Pharmaceuticals, Inc. March 26, 2007
Solvay Pharmaceuticals, Inc. announced today that Victor F. C. Raczkowski, M.D., M.S., has been named vice president of U.S. Regulatory Affairs. In this role, Raczkowski will provide regulatory leadership and direction for the U.S. commercial business, assure U.S. regulatory compliance, and be responsible for all activities and interactions associated with the U.S. Food and Drug Adminstration (FDA).
Florence S. Gilson Named Vice President of Quality Assurance/Quality Control for Solvay Pharmaceuticals December 13, 2006
Florence S. Gilson has been promoted to vice president of quality assurance/quality control, the Americas, for Solvay Pharmaceuticals. In this role, Gilson assumes responsibility for quality assurance and quality control activities for the company in the United States, Canada, Mexico and Brazil.
Solvay Pharmaceuticals and Wyeth announce submission of new drug application for Bifeprunox to treat schizophrenia October 12, 2006
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announce today that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) for bifeprunox, an investigational, new generation atypical antipsychotic for treatment and maintenance of stability of schizophrenic patients.
Solvay Pharmaceuticals Settles Lawsuit Against Pseudo-Generic to CREON® MINIMICROSPHERES® July 11, 2006
Solvay Pharmaceuticals, Inc. announced today that it has settled a lawsuit filed against Global Pharmaceuticals and Impax Laboratories, Inc. alleging that the companies falsely advertised and marketed their products as generic equivalents to and substitutes for Solvay Pharmaceuticals’ CREON® MINIMICROSPHERES® (Pancrelipase Delayed-release Capsules, USP).
Laurence Downey, MD, Named to PhRMA Board of Directors June 06, 2006
Solvay Pharmaceuticals, Inc. announced today that Laurence Downey, MD, president and chief executive officer, has been named to the board of directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). Downey will serve a three-year term from April 2006 to April 2009.
Solvay Pharmaceuticals, Inc. Names Laurence Downey, M.D. as New President and CEO January 04, 2006
Solvay Pharmaceuticals, Inc. announced today the appointment of Laurence Downey, M.D. as President and CEO, effective Jan. 1, 2006. Downey succeeds Harold H. Shlevin, Ph.D., who has taken on a position of global responsibility within the Solvay Group.
Solvay Pharmaceuticals, Inc. Awards 2005 "Challenge Match" Donation December 16, 2005
Solvay Pharmaceuticals, Inc. has awarded a $10,000 grant to Lake of the Woods (LOW) Independent School District (ISD) #390 again this year for use in supporting the Enrichment Program for Gifted and Talented Students at LOW School.
FDA Extends PDUFA Date for ACEON® by 90 Days June 20, 2005
Solvay Pharmaceuticals, Inc. and CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that the U.S. Food and Drug Administration (FDA) has informed Solvay Pharmaceuticals that the FDA has extended the Prescription Drug User Fee Act (PDUFA) date for the ACEON® (perindopril erbumine) Tablets supplemental new drug application (sNDA) by 90 days, and the PDUFA date is now September 10, 2005.
New Data Show Low Testosterone More Likely in Men with Diabetes June 11, 2005
Men with diabetes age 45 and older may be more than twice as likely as non-diabetic men to have low testosterone levels, according to new data announced at the American Diabetes Association Annual Meeting and Scientific Session in San Diego.
Data Show New Synthetic Delta-9-THC Inhaler Offers Safe, Rapid Delivery April 14, 2005
Solvay Pharmaceuticals, Inc. today announced the results of a Phase I study evaluating the safety and tolerability of pulmonary dronabinol administered in a one-time dose using a pressurized metered dose inhaler.
Solvay Pharmaceuticals Unimed Pharmaceuticals Join National Program to Help Millions of Uninsured Americans April 11, 2005
Solvay Pharmaceuticals, Inc. and its wholly owned subsidiary Unimed Pharmaceuticals, Inc., today announced their participation in the Partnership for Prescription Assistance, the largest-ever private-sector program to help patients who lack prescription coverage, joining a national coalition of pharmaceutical companies, doctors, nurses, other health care providers, pharmacists, patient advocates and community leaders.
Unimed Pharmaceuticals, Inc. Reports AndroGel® Long-term Safety and Benefits May 04, 2004
Unimed Pharmaceuticals, Inc., a wholly owned subsidiary of Solvay Pharmaceuticals, Inc., today reported that a three-year research study showed AndroGel® (testosterone gel) 1% CIII is safe and effective for men with hypogonadism, or low testosterone.
CREON® FAMILY SCHOLARSHIP APPLICATIONS NOW AVAILABLE April 05, 2004
Solvay Pharmaceuticals, Inc. has announced the availability of applications for its 2004-2005 CREON® MINIMICROSPHERES® (pancrelipase delayed-release capsules, USP) Family Scholarship Program.
Solvay Pharmaceuticals, Inc. Receives U.S. FDA Approval for EstroGel® February 10, 2004
Solvay Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EstroGel® (estradiol gel), the first-ever estrogen therapy transdermal gel in the country for the treatment of moderate to severe vasomotor symptoms, as well as vulvar and vaginal atrophy associated with the menopause.
Unimed Pharmaceuticals, Inc. Receives Patent on AndroGel® January 09, 2003
Unimed Pharmaceuticals, Inc., a wholly owned subsidiary of Solvay Pharmaceuticals, Inc., today announced that the United States Patent and Trademark Office has granted a composition of matter patent for Unimed's product AndroGel® 1% (testosterone gel) CIII.
Crohn's Colitis Foundation of America Announces Local Heroes October 28, 2002
The Crohn's Colitis Foundation of America (CCFA), in partnership with Solvay Pharmaceuticals, Inc., has announced the winners of the second annual "Local Hero Patient Celebration Program."
Unimed Pharmaceuticals, Inc. Announces Management Change August 30, 2001
Unimed Pharmaceuticals, Inc., a wholly owned, independently operated subsidiary of Solvay Pharmaceuticals, Inc., announces the promotion of Jean-Louis Anspach to president and CEO.
Resumed Cilansetron Phase III Clinical Program July 19, 2001
Solvay Pharmaceuticals, Inc. has decided to move forward with its phase III clinical program for cilansetron, an experimental drug for diarrhea-predominant irritable bowel syndrome (IBS) in both men and women.
Unimed Pharmaceuticals, Inc. to Be Sole Marketer of Marinol® January 02, 2001
Unimed Pharmaceuticals, Inc. announced today that effective January 1, 2001, it has become solely responsible for the marketing of Marinol® CIII (dronabinol) capsules.
